```html

Venous Thromboembolism (VTE)

Overview

Venous thromboembolism (VTE) is an umbrella term that includes two related conditions: deep‑vein thrombosis (DVT), a blood clot that forms in the deep veins—most often of the legs, and pulmonary embolism (PE), when part of that clot breaks free and travels to the lungs.

VTE is a leading cause of preventable death and disability worldwide. In the United States, an estimated ≈ 900,000 cases occur each year, resulting in roughly 100,000 deaths. The incidence rises sharply with age: adults ≥ 65 years have a 1‑ to 2‑percent annual risk, compared with <0.1 % in people under 40.

It can affect anyone, but certain groups—those with recent surgery, cancer, prolonged immobility, or inherited clotting disorders—are disproportionately affected.

Symptoms

Symptoms differ between DVT and PE. Because clots can be silent, any new, unexplained change in leg or respiratory status warrants evaluation.

Deep‑Vein Thrombosis (DVT)

• Pain or tenderness in the calf, thigh, or groin—often described as a cramp or achy sensation.
• Swelling of the affected leg, usually unilateral.
• Warmth and redness over the area.
• Visible surface veins (collateral circulation) that may become more prominent.
• Occasionally, a *“popping”* sensation when the clot forms, though this is rare.

Pulmonary Embolism (PE)

• Sudden shortness of breath that is out of proportion to activity.
• Sharp chest pain that may worsen with deep breathing (pleuritic pain).
• Rapid heart rate (tachycardia).
• Cough, sometimes producing blood‑streaked sputum.
• Light‑headedness, fainting, or sudden collapse.
• Low‑grade fever (usually <38 °C/100.4 °F) may accompany larger emboli.

Causes and Risk Factors

VTE results from a combination of blood stasis, hypercoagulability, and endothelial injury—known as **Virchow’s triad**.

Major Causes

• Immobilization— prolonged bed rest, long‑haul travel, or casting.
• Surgery— particularly orthopedic (hip, knee) and abdominal/pelvic procedures.
• Cancer— solid tumors (especially pancreatic, lung, ovarian) and hematologic malignancies increase clotting factors.
• Inherited thrombophilias— Factor V Leiden, prothrombin G20210A mutation, antithrombin deficiency.
• Hormonal influences— oral contraceptives, hormone replacement therapy, pregnancy, and the postpartum period.
• Obesity— BMI ≥ 30 kg/m² raises venous pressure and inflammation.
• Chronic medical conditions— heart failure, inflammatory bowel disease, nephrotic syndrome.
• Central venous catheters or other intravascular devices.

Risk Factors by Population

Population	Key Risk Factors
Older adults (≥65 y)	Reduced mobility, comorbidities, higher prevalence of cancer.
Post‑surgical patients	Operative trauma, anesthesia‑induced stasis.
Cancer patients	Tumor‑released pro‑coagulants, chemotherapy.
Pregnant & postpartum women	Elevated estrogen, venous compression by uterus.
People with inherited clotting disorders	Genetic hypercoagulability.

Diagnosis

Diagnosing VTE relies on a structured approach that combines clinical assessment, risk‑scoring tools, and imaging or laboratory testing.

Clinical Prediction Rules

• Wells Score for DVT and PE— stratifies patients into low, moderate, or high probability.
• Revised Geneva Score— used when clinician‑subjective elements of the Wells score are undesirable.

Laboratory Tests

• D‑dimer— a fibrin degradation product. A normal value effectively rules out VTE in low‑risk patients, but elevation is nonspecific.
• Complete blood count, metabolic panel— assess anemia, renal function (important for anticoagulant dosing).
• Coagulation studies— PT/INR, aPTT, especially before initiating warfarin.

Imaging Studies

• Compression ultrasonography (CUS)— first‑line for suspected lower‑extremity DVT; demonstrates lack of compressibility.
• CT Pulmonary Angiography (CTPA)— gold standard for PE; visualizes intraluminal filling defects.
• Ventilation‑Perfusion (V/Q) scan— alternative when contrast is contraindicated.
• Magnetic resonance venography (MRV)— used for pelvic or upper‑extremity DVT when ultrasound is limited.

Treatment Options

Prompt treatment reduces mortality and prevents long‑term complications such as post‑thrombotic syndrome.

Anticoagulant Medications

• Direct oral anticoagulants (DOACs) – apixaban, rivaroxaban, edoxaban, dabigatran. Preferred for most patients due to fixed dosing and no regular monitoring.
• Low‑molecular‑weight heparin (LMWH) – enoxaparin, dalteparin. Often used in cancer‑associated VTE and during pregnancy.
• Unfractionated heparin (UFH) – intravenous infusion; useful for rapid reversal or in severe renal impairment.
• Warfarin – vitamin K antagonist; requires INR monitoring (target 2.0‑3.0). Reserved when DOACs are contraindicated.

Procedural Interventions

• Catheter‑directed thrombolysis – high‑dose clot‑dissolving agents delivered locally for massive PE or extensive ilio‑femoral DVT.
• Mechanical thrombectomy – device‑based clot removal, indicated in life‑threatening PE when thrombolysis is contraindicated.
• Inferior vena cava (IVC) filter – placed when anticoagulation is impossible or fails; prevents clots from reaching the lungs.

Supportive Measures

• Compression stockings (30‑40 mmHg) – help prevent post‑thrombotic syndrome after DVT.
• Early ambulation – reduces stasis once pain is controlled.
• Pain control – acetaminophen or short courses of NSAIDs, avoiding agents that increase bleeding risk.

Living with Venous Thromboembolism (VTE)

After the acute phase, most patients transition to long‑term management. The following tips help maintain safety and quality of life.

• Adhere to medication schedules. Set alarms or use a pill‑box. Do not stop an anticoagulant without a clinician’s order.
• Monitor for bleeding. Watch for unusual bruising, pink‑or‑red urine or stool, prolonged nosebleeds, or gum bleeding.
• Stay active. Aim for at least 150 minutes of moderate‑intensity aerobic activity per week, broken into shorter bouts if necessary.
• Maintain a healthy weight. Even modest weight loss (5‑10 % of body weight) reduces recurrence risk.
• Hydration. Adequate fluid intake helps keep blood less viscous, especially during travel.
• Regular follow‑up. Lab monitoring (e.g., renal function for DOACs, INR for warfarin) every 1‑3 months, or as directed.
• Travel precautions. Wear graduated compression stockings, stand and stretch every 1‑2 hours, and consider prophylactic LMWH for very long trips if you’re high risk.

Prevention

Because many VTE events are preventable, risk‑reduction strategies are a cornerstone of care.

For the General Population

• Engage in regular physical activity—walking, cycling, swimming.
• Maintain a BMI < 30 kg/m².
• Quit smoking; it increases platelet activation and endothelial dysfunction.
• Stay well‑hydrated, especially in hot climates or during long flights.

Medical / Surgical Settings

• Pharmacologic prophylaxis – low‑dose LMWH, fondaparinux, or aspirin per guideline‑based risk assessment (American College of Chest Physicians, 2022).
• Mechanical prophylaxis – intermittent pneumatic compression devices or graduated compression stockings when anticoagulants are contraindicated.
• Early mobilization – get patients out of bed and walking as soon as feasible post‑operatively.

Special Situations

• Pregnancy – LMWH prophylaxis for women with prior VTE or high‑risk thrombophilia.
• Cancer – continue LMWH or switch to a DOAC (e.g., apixaban) unless contraindicated.
• Inherited thrombophilia – discuss long‑term anticoagulation with a hematologist, especially after a first event.

Complications

If VTE is not promptly recognized and treated, serious sequelae can develop.

• Pulmonary embolism mortality – massive PE carries a 30‑50 % case‑fatality rate.
• Post‑thrombotic syndrome (PTS) – chronic leg pain, swelling, skin changes, and ulceration occurring in up to 50 % of untreated DVT patients.
• Recurrent VTE – risk is highest in the first 3 months after the initial event; can be as high as 10‑15 % without adequate anticoagulation.
• Chronic thromboembolic pulmonary hypertension (CTEPH) – persistent obstruction of pulmonary arteries leading to right‑heart failure; occurs in 2‑4 % of PE survivors.
• Bleeding complications – paradoxically, anticoagulation can cause major bleeding; balancing risk is essential.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, National Institutes of Health (NIH), World Health Organization (WHO), American College of Chest Physicians (ACCP) guidelines, Cleveland Clinic, The New England Journal of Medicine, Blood journal. All information is for educational purposes and does not replace professional medical advice.

```